HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. - Wikidata - wikimedia - TriplyDB

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

http://www.wikidata.org/entity/Q35111575

about

HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach Surgery in the era of the 'omics revolution Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies.Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.High expression of carbonic anhydrase IX is significantly associated with glandular lesions in gastroesophageal junction and with tumorigenesis markers BMI1, MCM4 and MCM7 The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer.Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma.Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma Association of CHRNA5-A3-B4 variation with esophageal squamous cell carcinoma risk and smoking behaviors in a Chinese population.Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis.Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients.Bile salt receptor TGR5 is highly expressed in esophageal adenocarcinoma and precancerous lesions with significantly worse overall survival and gender differences.Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer.Advances in biomarkers for esophageal cancer.Selection of a novel DNA thioaptamer against HER2 structure.Surgical and Molecular Pathology of Barrett Esophagus.Digital image analysis of HER2 immunohistochemistry in gastric- and oesophageal adenocarcinoma: a validation study on biopsies and surgical specimens.Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays.Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer.The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study.Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma.Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice.Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.Genome-wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis.HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor.Early HER2 dysregulation in gastric and oesophageal carcinogenesis New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment

P2860

Q26741253-300FF6E0-73DC-42B9-A565-A868942AF2CE Q26780318-04FFC439-FF12-47CE-907A-68F676F7395C Q26852061-40AD920B-FFD3-4ADB-BED5-4F9A2876A712 Q27026253-72A40E20-EDA4-4E4D-A418-0FE525EBCCC9 Q28085367-3BE8BF8F-0CB9-4410-84EF-F6985D6CAB72 Q33863322-0651CEDB-97FD-4003-ADBD-63AA7B94E3E4 Q34324291-49C7B4F2-956B-423E-8C38-67D0573BCC1F Q35145369-7EA8123D-AD88-4366-9485-77D47AFA27B8 Q35151182-D9B7BBA6-F3AE-456E-979D-BEFAC5B76BED Q35681702-FD515E51-E7A2-4DBE-8642-858F2F7CED6E Q35686653-83B22770-8819-46F8-90E3-D7F14E596A9F Q36064912-C90A5494-2B41-4689-A097-F18FD8799CCD Q36140927-E955D1A1-8EEF-492D-90DB-BCD87A9BDC81 Q36666667-A766EA5B-394A-4C1E-B004-38EFCAD701A0 Q36910400-0D126D32-3109-4EF8-8D20-59CE983A5342 Q36976709-8372870A-95CA-4A16-A633-DD62024B90A6 Q37038482-F973C3A4-38B9-4EAB-9F86-BFBB6A6F8B03 Q37522215-D6D73F24-287B-484A-B094-5BDFB4CC289F Q37523508-787B479A-E770-42D6-9BBB-1B7178E7BFF2 Q37638724-1F32B221-98CE-4C95-9965-4B2B5FD87139 Q38030442-A813A832-1473-4595-ABDB-DDCF00ACD407 Q38153443-DF1CCEA0-8BE5-48B7-B281-AD00ACE1D90E Q38298656-16512F58-8D39-488A-9468-AA43F479BC00 Q38526018-B4BFA536-ABC1-4F59-B7FD-6E1A9C3D2D49 Q40107322-7926D77F-3C22-457C-ABE9-EDEDBB52A6B4 Q40886552-4A050019-1CD7-4276-948B-1630DA95C94C Q43494045-3A52EA7A-CB89-451D-BD53-4634FCBC62DB Q43500705-1B0040EF-C722-4791-B4DE-BD913F51BBBC Q43551349-635B3A2C-9E0D-472F-B45C-884671941684 Q43635123-767EE8CC-71B8-4824-AE20-9F54D4B6696B Q44522454-3469F1D8-77FD-4ABA-853E-F1965B09711E Q51121654-EDE4804B-CC0C-41D5-942A-757320A7487B Q53657591-24CB8972-1AA6-4EF4-9378-63D78682CACE Q54953740-6C2DA3C5-A49D-465C-B9F5-3388EB65003C Q58003579-6B362072-C6D0-4A5D-AF88-449F4521A1A5 Q58783978-B3535A8D-2434-4993-AF8E-7FAC00A1ECB1

P2860

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

http://www.wikidata.org/entity/Q35111575

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

@ast

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

@en

type

label

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

@ast

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

@en

prefLabel

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

@ast

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

@en

P1433

Q35111575-7889C08C-5C9F-426C-9CCB-A98B11457C3C

P1476

Q35111575-099FE8FF-B617-4D7A-8874-D3EC23F29AEA

P2093

Q35111575-5F8995B6-0292-44BF-81AC-53799BBFC537

Q35111575-6A641865-7319-4DCC-BCE1-91C22F597CD3

Q35111575-6C88FD3F-7F08-4D5E-A49F-9B00A6818ADA

Q35111575-820380B3-28DD-45E4-B955-D7D02A15094D

Q35111575-9F6586D2-0B69-48E5-87D8-4DF92DEBF409

Q35111575-A1854FDB-4312-40B7-A40B-ABAEFF08EC65

Q35111575-B5611BCC-EC9B-4D02-AAEE-912D3E9E0DEA

Q35111575-B769E3C1-56CE-4C7D-891D-E71C09E6122C

Q35111575-C8F51579-9A98-4056-A936-0C996557616C

P2860

Q35111575-0080D2D2-EB23-4048-9B0D-7C674AD496C1

Q35111575-01F2CC16-E0D1-4AB2-9F62-0120FF57148B

Q35111575-091881A3-C3DE-4173-B67A-C44329B82D81

Q35111575-0D43950F-2FB5-46FF-99F7-C75D87C01E19

Q35111575-1EF005F0-2FC8-4B94-BE89-FB6036AB8A27

Q35111575-3EE7442E-4AEE-4CD1-A805-04463EE3D8FA

Q35111575-3F1F62F0-B335-44AC-83DD-AA45DF21E697

Q35111575-40F68B42-DE82-4C86-9976-F7F1215C9909

Q35111575-43626AC7-25E1-4F63-A3D6-222A8889888E

Q35111575-44F63FC4-AE57-4238-8D3C-0309566631DD

P2888

Q35111575-8B6D6B47-76D0-4BA9-B795-53571DAB1BE8

P304

Q35111575-6C7FE3A6-B0AD-4064-B355-23777F8422C4

P31

Q35111575-15733709-8F53-4877-AD77-B4E4B3004120

P356

Q35111575-0D671860-F602-4F1E-98DC-7FAB09D913FB

P433

Q35111575-5F114051-A13C-4642-9E95-7C25716BB8DE

P478

Q35111575-F99F4EA2-207E-4405-ABA8-164A7C8EC94C

P50

Q35111575-CEB4BEE2-DB7B-40D3-9CB9-BB255AF825E9

P577

Q35111575-9AE3F06C-11F6-4E1E-B8A1-21875060EC3F

P5875

Q35111575-7B9BAA63-88E5-42E3-8613-3039220AD069

P698

Q35111575-304F595E-94D9-4E4F-9A08-283423B3C648

P921

Q35111575-515916C2-D5A1-4E87-A0D9-2D38CF60F452

Q35111575-9AA43226-E21B-40F9-9B81-ECCD7D917452

P932

Q35111575-05D3A6BE-150A-4772-A88B-2A1F2CAB2CAD

P356

MODPATHOL.2011.47

P1433

Modern Pathology

P1476

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma

@en

P2093

Arjun Pennathur

http://www.w3.org/2001/XMLSchema#string

David G Hicks

http://www.w3.org/2001/XMLSchema#string

Dongfeng Tan

http://www.w3.org/2001/XMLSchema#string

James D Luketich

http://www.w3.org/2001/XMLSchema#string

Jeffrey H Peters

http://www.w3.org/2001/XMLSchema#string

Santhoshi Bandla

http://www.w3.org/2001/XMLSchema#string

Xing Qiu

http://www.w3.org/2001/XMLSchema#string

Yingchuan Hu

http://www.w3.org/2001/XMLSchema#string

Zhongren Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus

Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation.

Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study.

HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study.

Multimodality treatment of esophageal cancer.

P2888

modpathol.2011.47

P304

899-907

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2011.47

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50989682

http://www.w3.org/2001/XMLSchema#string

P698

21460800

http://www.w3.org/2001/XMLSchema#string

P921

P932

3138485

http://www.w3.org/2001/XMLSchema#string